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Summary
Background Carboplatin and paclitaxel administered every 3 weeks is standard-of-care first-line chemotherapy for 
epithelial ovarian cancer. The Japanese JGOG3016 trial showed a significant improvement in progression-free and 
overall survival with dose-dense weekly paclitaxel and 3-weekly carboplatin. In this study, we aimed to compare 
efficacy and safety of two dose-dense weekly regimens to standard 3-weekly chemotherapy in a predominantly 
European population with epithelial ovarian cancer.
Methods In this phase 3 trial, women with newly diagnosed International Federation of Gynecology and Obstetrics 
stage IC–IV epithelial ovarian cancer were randomly assigned to group 1 (carboplatin area under the curve [AUC]5 or 
AUC6 and 175 mg/m² paclitaxel every 3 weeks), group 2 (carboplatin AUC5 or AUC6 every 3 weeks and 80 mg/m² 
paclitaxel weekly), or group 3 (carboplatin AUC2 and 80 mg/m² paclitaxel weekly). Written informed consent was 
provided by all women who entered the trial. The protocol had the appropriate national research ethics committee 
approval for the countries where the study was conducted. Patients entered the trial after immediate primary surgery, 
or before neoadjuvant chemotherapy with subsequent planned delayed primary surgery. The trial coprimary outcomes 
were progression-free survival and overall survival. Data analyses were done on an intention-to-treat basis, and were 
powered to detect a hazard ratio of 0·75 in progression-free survival. The main comparisons were between the control 
group (group 1) and each of the weekly research groups (groups 2 and 3). 
Findings Between June 6, 2011, and Nov 28, 2014, 1566 women were randomly assigned to treatment. 72% (365), 
completed six protocol-defined treatment cycles in group 1, 60% (305) in group 2, and 63% (322) in group 3, although 
90% (454), 89% (454), and 85% (437) completed six platinum-based chemotherapy cycles, respectively. Paclitaxel dose 
intensification was achieved with weekly treatment (median total paclitaxel dose 1010 mg/m² in group 1; 1233 mg/m² 
in group 2; 1274 mg/m² in group 3). By February, 2017, 1018 (65%) patients had experienced disease progression. No 
significant progression-free survival increase was observed with either weekly regimen (restricted mean survival time 
24·4 months [97·5% CI 23·0–26·0] in group 1, 24·9 months [24·0–25·9] in group 2, 25·3 months [23·9–26·9] in 
group 3; median progression-free survival 17·7 months [IQR 10·6–not reached] in group 1, 20·8 months [11·9–59·0] 
in group 2, 21·0 months [12·0–54·0] in group 3; log-rank p=0·35 for group 2 vs group 1; group 3 vs 1 p=0·51). 
Although grade 3 or 4 toxic effects increased with weekly treatment, these effects were predominantly uncomplicated. 
Febrile neutropenia and sensory neuropathy incidences were similar across groups.
Interpretation Weekly dose-dense chemotherapy can be delivered successfully as first-line treatment for epithelial 
ovarian cancer but does not significantly improve progression-free survival compared with standard 3-weekly 
chemotherapy in predominantly European populations.
Funding Cancer Research UK, Medical Research Council, Health Research Board in Ireland, Irish Cancer Society, 
Cancer Australia.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
Introduction
Epithelial ovarian cancer is the most common cause of 
gynaecological cancer-related death in high-income 
countries.1 The majority of women with ovarian cancer 
present with advanced disease and, despite primary 
multimodality treatment with cytoreductive surgery and 
chemotherapy, most patients experience disease relapse 
within 2 years of diagnosis. For more than two decades, 
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platinum–paclitaxel doublet chemotherapy administered 
every 3 weeks for six to eight cycles has been the reference 
standard of care first-line treatment for ovarian cancer.2,3 
Chemotherapy is most commonly administered after 
primary surgery. However, in women for whom complete 
primary cytoreduction is deemed unlikely, delayed surgery 
after three to four primary (neoadjuvant) chemotherapy 
cycles has been widely adopted. This approach follows 
publication of two randomised trials4–6 showing that 
overall survival is not inferior to upfront surgery and is 
associated with less perioperative morbidity. It is, 
therefore, important that first-line trials include the option 
of primary chemotherapy.
In the past decade, there has been significant interest in 
the evaluation of weekly dose-dense paclitaxel scheduling. 
Preclinical evidence suggests that metronomic taxane 
administration improves drug delivery, increases tumour 
cell apoptosis, and reduces angiogenesis.7,8 Weekly 
paclitaxel treatment is an efficacious and well tolerated 
approach in recurrent platinum-resistant ovarian cancer,9–11 
and confers a survival advantage compared with 3-weekly 
scheduling in both the adjuvant and metastatic settings 
for breast cancer.12,13
The JGOG3016 trial14,15 randomly assigned 637 Japanese 
women with newly diagnosed epithelial ovarian cancer to 
receive conventional 3-weekly (ie, once every 3 weeks) 
carboplatin–paclitaxel chemotherapy or an investigational 
group in which weekly dose-dense paclitaxel at a dose of 
80 mg/m² was administered with 3-weekly carboplatin. 
Weekly treatment resulted in an 11-month prolongation 
of median progression-free survival and a corresponding 
38-month improvement in median overall survival. 
However, weekly dose-dense treatment caused more 
haematological and neurological toxic effects, which 
compromised the ability to deliver six cycles of treatment. 
In contrast, the evaluation of weekly scheduling of both 
carboplatin and paclitaxel in phase 2 trials showed both 
excellent tolerability and promising efficacy.16,17
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Research in context
Evidence before this study
Carboplatin and paclitaxel administered every 3 weeks has been 
a standard component of first-line epithelial ovarian cancer 
treatment for more than 20 years. Preclinical studies showed 
that metronomic taxane scheduling improved drug delivery, 
increased tumour apoptosis, and decreased angiogenesis. 
We searched PubMed for clinical trials published between 
Jan 1, 1990, and Dec 31, 2018, using the terms “ovarian cancer” 
AND “chemotherapy” AND “paclitaxel” AND “progression-free 
survival”, to identify phase 3 trials which evaluated weekly 
dose-dense paclitaxel scheduling throughout first-line epithelial 
ovarian cancer treatment. Three relevant trials were identified.
The Japanese JGOG3016 trial randomly assigned women with 
International Federation of Gynecology and Obstetrics (FIGO) 
stage II–IV epithelial ovarian cancer to 3-weekly 
carboplatin–paclitaxel or a regimen incorporating weekly 
paclitaxel (delivered to a higher total dose), and 3-weekly 
carboplatin. Clinically significant improvements in 
progression-free survival and overall survival were reported. 
However, weekly paclitaxel was associated with increased 
toxicity, which negatively affected treatment delivery.
MITO-7, a European trial, randomly assigned women with 
stage IC–IV epithelial ovarian cancer to 3-weekly 
carboplatin–paclitaxel or both drugs given weekly with the 
same planned total paclitaxel dose. No progression-free 
survival difference was reported. Weekly chemotherapy was 
better tolerated and associated with improved quality of life. 
However, the lack of paclitaxel dose intensification and weekly 
carboplatin scheduling might have negatively affected the 
outcome of the weekly treatment.
GOG-262, an American study, randomly assigned women with 
stage II-IV epithelial ovarian cancer to 3-weekly 
carboplatin–paclitaxel or weekly treatment identical to 
JGOG3016. 84% of GOG-262 participants opted to receive the 
anti-angiogenic bevacizumab, in addition to chemotherapy. 
No progression-free survival difference was observed between 
treatment groups, although weekly paclitaxel was better 
tolerated than in JGOG3016. However, in the subgroup who did 
not receive bevacizumab, weekly paclitaxel improved 
progression-free survival. It is not possible to conclude whether 
the use of maintenance bevacizumab masked a weekly 
paclitaxel treatment effect in the whole trial population.
Added value of this study
In ICON8, 1566 women with FIGO stage IC–IV epithelial ovarian 
cancer were randomly assigned to 3-weekly carboplatin–
paclitaxel, 3-weekly carboplatin and weekly dose-dense 
paclitaxel (replicating the JGOG3016 weekly regimen), or 
weekly carboplatin with weekly dose-dense paclitaxel. Patients 
entered ICON8 after immediate primary surgery or received 
neoadjuvant chemotherapy with delayed primary surgery. 
Neither weekly regimen improved progression-free survival 
compared with standard 3-weekly treatment. Although most 
patients were able to complete six chemotherapy cycles, both 
weekly treatments were associated with more treatment 
modifications and a higher incidence of grade 3 or higher toxic 
effects.
Implications of all the available evidence
Weekly dose-dense paclitaxel should no longer be 
recommended as a component of first-line epithelial ovarian 
cancer treatment for women of non-Japanese ethnic origin. 
Because potential ethnic pharmacogenomic differences might 
affect the efficacy and toxicity of paclitaxel, dose-dense 
paclitaxel could remain a first-line treatment option for 
Japanese women with ovarian cancer.
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(ICON8) trial was designed to evaluate whether the 
incorporation of dose-dense weekly paclitaxel into first-
line treatment of ovarian cancer in a predominantly 
European patient group would improve survival out-
comes, and to determine whether weekly scheduling 
of carboplatin would reduce haematological toxicity, 
improve deliverability, and maintain the efficacy of dose-
dense paclitaxel.
Methods
Study design and participants
ICON8 was an international, open-label, randomised 
phase 3, three-arm trial of weekly dose-dense chemo-
therapy as first-line treatment in patients with histo-
logically confirmed epithelial ovarian, primary peritoneal, 
or fallopian tube carcinoma (herein collectively termed 
ovarian cancer). Patients were recruited from 117 sites in 
the UK, Australia, New Zealand, Mexico, South Korea, 
and Republic of Ireland (appendix pp 6, 7). All patients 
were 18 years or older, had International Federation of 
Gynecology and Obstetrics (FIGO; 1988) stage IC–IV 
cancer (with mandatory high-risk histological subtype 
for patients with FIGO 1988 stage IC or IIA disease); 
had an Eastern Cooperative Oncology Group (ECOG) 
performance status of 0–2; life expectancy longer than 
12 weeks; and adequate haematological, renal, and hepatic 
functions; and be able to start chemotherapy within 
8 weeks after IPS. They had not received previous 
systemic therapy for ovarian cancer and were not planned 
to receive maintenance treatment after completion of 
protocol therapy. All patients gave written informed 
consent to join the trial.
In the UK, ethical approval was granted by the London–
Chelsea research ethics committee. The trial  also re-
ceived ethical approval from appropriate national or local 
institutional review boards in other jurisdictions. The 
protocol can be found online. 
Randomisation and masking
Patients were randomly assigned (1:1:1) to one of 
three treatment groups: group 1 (control) for 3-weekly 
carboplatin area under the curve (AUC)5 or AUC6 and 
3-weekly paclitaxel 175 mg/m²; group 2 for 3-weekly 
carboplatin AUC5 or AUC6 and weekly paclitaxel 
80 mg/m²; and group 3 for weekly carboplatin AUC2 
and weekly paclitaxel 80 mg/m², given in all groups for 
six cycles. Patients were randomly assigned using the 
Medical Research Council Clinical Trials Unit (MRC CTU) 
at University College London (UCL) randomisation tele-
phone service; the method of minimisation was used 
with stratification factors of GCIG group, disease stage 
(FIGO stage IC high grade serous, clear cell, or grade III 
carcinoma; FIGO stage IIA high grade serous, clear cell, 
or grade III carcinoma; FIGO stage IIB; FIGO stage IIC; 
FIGO stage IIIA; FIGO stage IIIB; FIGO stage IIIC; FIGO 
stage IV), and outcome and timing of surgery (IPS plus 
FIGO stage IC–III with no visible residual disease; IPS 
plus FIGO stage IC–III with residual disease ≤1 cm; IPS 
plus FIGO stage IV or FIGO stage IC–III with residual 
disease >1 cm; no surgery currently planned; or DPS is 
planned). Patients and clinicians were not masked to their 
allocated group.
Procedures
Patients were able to enter the trial after upfront 
(immediate) primary cytoreductive surgery (IPS) or could 
receive primary (neoadjuvant) chemotherapy with a plan 
for delayed primary cytoreductive surgery (DPS) at the 
decision of the local multidisciplinary gynaecological 
oncology team. Patients were also eligible for the trial if 
there was no plan for surgery.
All participants started chemotherapy within 2 weeks 
of randomisation. Patients in group 1 received carboplatin 
AUC5 or AUC6 by intravenous infusion over 30–60 min 
and paclitaxel 175 mg/m² by intravenous infusion over 
3 h on day 1 of a 21-day cycle for six cycles; patients in 
group 2 received carboplatin as in group 1 and dose-
fractionated paclitaxel 80 mg/m² by intravenous infusion 
over 1 h on days 1, 8, and 15 of a 21-day cycle for six cycles; 
and patients in group 3 received carboplatin AUC2 by 
intravenous infusion over 30–60 min on day 1 and 
paclitaxel 80 mg/m² by intravenous infusion over 1 h on 
days 1, 8, and 15 of a 21-day cycle for six cycles. Carboplatin 
dose was calculated using the Calvert formula with 
starting AUC determined by the method used to calculate 
renal function at trial entry: AUC5 for radioisotopic 
glomerular filtration rate, measured 24 h urinary 
creatinine clearance and Wright formula estimation, and 
AUC6 for modified Cockcroft-Gault or Jelliffe formula 
estimation.18–21 
In all groups, treatment proceeded on day 1 of each 
cycle if absolute neutrophil count (ANC) was 1·0 × 10⁹ cells 
per L or more and platelet count was 75 × 10⁹ cells per L or 
more. In group 2, paclitaxel was administered at days 8 
and 15 if ANC was 0·5 × 10⁹ cells per L or more and 
platelets 50 × 10⁹ cells per L or more; if these haemato-
logical parameters were not met, paclitaxel was omitted. 
In group 3, day 8 and day 15 weekly carboplatin and 
paclitaxel were administered if ANC was 1·0 × 10⁹ cells 
per L or more and platelet count 75 × 10⁹ cells per L or 
more; both drugs were deferred if these values were 
not achieved. Protocol-defined dose alterations (delay, 
reduction, omissions) were allowed for haematological 
and other toxic effects if deemed clinically necessary. 
Single-agent carboplatin was accepted as protocol 
treatment if patients were unable to tolerate paclitaxel. In 
the event of carboplatin hypersensitivity, trial manage-
ment guidelines allowed continuation of carboplatin 
with increased hyper sensitivity prophylaxis, the use of a 
formal carboplatin desensitisation regimen, or a switch 
to cisplatin for severe or recurrent hypersensitivity.
Surgery was done either as IPS, ie, before randomisation, 
followed by six cycles of chemotherapy; or as planned 
DPS, ie three cycles of chemotherapy, followed by surgery, 
See Online for appendix
For the study protocol see 
https://www.ctu.mrc.ac.uk/
studies/all-studies/i/icon8/
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which was subsequently followed by a further three cycles 
of chemotherapy; however, surgery could be done at 
a later date if deemed clinically appropriate. Day 15 
treatment was omitted from the chemotherapy cycle 
before DPS to prevent chemotherapy-related toxic effects 
affecting surgical timing and it was recommended that 
surgery was done within 32 days of the start of the 
presurgery chemotherapy cycle.
During chemotherapy, patients were seen 3-weekly 
before administration of day 1 of each chemotherapy 
cycle, and an end-of-treatment visit occurred 6 weeks 
after day 1 of the last cycle of protocol chemotherapy. 
Thereafter, patients were followed up 6-weekly from the 
end of treatment visit until 9 months after randomi-
sation, then 3-monthly until 2 years after randomisation, 
then 6-monthly for a further 4 years, and annually 
thereafter. After disease progression, patients were 
followed up 6-monthly until 6 years and annually 
thereafter.
In all patients, baseline disease evaluation was done by 
abdominopelvic CT and chest radiograph. CT scans 
were repeated 6 weeks after the final cycle of protocol 
chemotherapy in all patients. In those receiving primary 
chemotherapy, two additional CT scans were done: after 
three cycles of chemotherapy to allow surgical planning 
and then 4 weeks after DPS. All imaging was reported 
using Response Evaluation Criteria in Solid Tumours 
(RECIST) version 1.1.22 Serum CA125 tumour marker 
measurements were done at baseline, on day 1 of each 
treatment cycle, and at each follow-up visit. During 
follow-up, routine imaging was not mandatory but was 
triggered by clinical symptoms suggestive of disease 
progression or when the GCIG criteria for CA125 
progression were met.23 Disease progression was defined 
by RECIST version 1.1 on the basis of radiological, 
clinical, or symptomatic indicators of disease progression 
and did not include isolated, asymptomatic CA125 
progression. For women in whom CA125 progression 
occurred in the absence of radiological progression by 
RECIST version 1.1, repeat imaging was mandated 
3-monthly until RECIST progression.
Outcomes
The trial had two co-primary outcomes: progression-
free survival and overall survival. For each outcome, 
two comparisons are made: group 2 versus group 1 and 
group 3 versus group 1. For both progression-free 
survival and overall survival, the timing of primary 
analyses was event-driven and required 602 events in 
each comparison. It was anticipated that the progression-
free survival analyses would occur approximately 2 years 
before the overall survival analyses. This Article reports 
the mature progression-free survival outcome and 
preliminary overall survival results.
Progression-free survival was calculated from the date 
of randomisation to the date of the first indication of 
disease progression or death from any cause, whichever 
occurred first in the intention-to-treat population (ie, all 
patients). Patients were censored on the date last seen, be 
that the date of last assessment when patient was 
confirmed to be alive with no progression, or the date a 
patient was confirmed to be lost to follow up or withdrawn 
from the trial.
Overall survival was calculated from date of 
randomisation to the date of death from any cause in the 
intention-to-treat population.
Preplanned secondary outcomes were safety, quality of 
life, and health economics (latter not reported in this 
Group 1 
(n=522)
Group 2 
(n=523)
Group 3 
(n=521)
Age, years 63 (55–68) 61 (54–67) 62 (53–68)
Participating group
UK 465 (89%) 468 (89%) 464 (89%)
Korea 10 (2%) 12 (2%) 10 (2%)
Ireland 9 (2%) 7 (1%) 8 (2%)
Australia and New Zealand 24 (5%) 23 (4%) 23 (4%)
Mexico 14 (3%) 13 (2%) 16 (3%)
Origin
Ovary (epithelial) 420 (81%) 424 (81%) 433 (83%)
Fallopian tube 24 (5%) 27 (5%) 21 (4%)
Primary peritoneal 77 (15%) 70 (13%) 65 (13%)
Missing data 1 (<1%) 2 (<1%) 2 (<1%)
Histological type
High-grade serous 
carcinoma
365 (70%) 346 (66%) 362 (69%)
Low-grade serous 
carcinoma
9 (2%) 11 (2%) 8 (2%)
Serous (no grade 
specified) carcinoma
8 (2%) 8 (2%) 9 (2%)
Clear cell 32 (6%) 41 (8%) 34 (7%)
Endometrioid 26 (5%) 19 (4%) 22 (4%)
Carcinosarcoma 2 (<1%) 7 (1%) 3 (1%)
Mixed or other types 80 (15%) 91 (17%) 83 (16%)
FIGO stage
IC or IIA 56 (11%) 56 (11%) 52 (10%)
IIB or IIC 47 (9%) 47 (9%) 37 (7%)
IIIA or IIIB 43 (8%) 55 (11%) 54 (10%)
IIIC 273 (52%) 266 (51%) 272 (52%)
IV 103 (20%) 99 (19%) 106 (20%)
ECOG performance status
0 246 (47%) 250 (48%) 235 (45%)
1 237 (45%) 230 (44%) 246 (47%)
2 37 (7%) 40 (8%) 39 (7%)
Missing data 2 (<1%) 3 (1%) 1 (<1%)
Timing of surgery
Immediate 251 (48%) 247 (47%) 248 (48%)
Delayed 257 (49%) 263 (50%) 259 (50%)
Inoperable 14 (3%) 13 (2%) 14 (3%)
Data are median (IQR), n (%), or n. FIGO=International Federation of Gynecology 
and Obstetrics. ECOG=Eastern Cooperative Oncology Group.
Table 1: Baseline characteristics
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Article). Adverse events were graded according to the 
National Cancer Institute Common Toxicity Criteria for 
Adverse Events (CTCAE) version 4, and were collected at 
baseline and at every chemotherapy cycle. Quality of life 
was collected using the European Organisation for 
Research and Treatment of Cancer quality-of-life 
questionnaire (QLQ)-C30, QLQ-OV28, and EQ5D tools at 
baseline, all chemotherapy cycles, and at all scheduled 
follow-up visits.
To evaluate treatment delivery, definitions of completed 
per-protocol treatment cycles were prespecified: in group 1 
the administration of both carboplatin and paclitaxel on 
day 1; in group 2 the administration of carboplatin on 
day 1 and at least two doses of weekly paclitaxel in a 3-week 
cycle; and in group 3 concurrent administration of at least 
two weekly doses of carboplatin and paclitaxel in a 3-week 
cycle. In addition, the number of completed platinum 
cycles, defined as all cycles in which an adequate 3-weekly 
dose of carboplatin (or cisplatin in those with severe or 
recurrent carboplatin hypersensitivity) was administered 
with or without paclitaxel, was recorded. Total dose 
received and dose intensities for carboplatin and paclitaxel 
were also calculated for each participant. Allowance was 
made for presurgery day 15 treatment omission in patients 
who underwent DPS.
Statistical analysis
ICON8 was powered to detect a hazard ratio [HR] of 
0·75 in both progression-free survival and overall 
survival. For both analyses, the main comparisons are 
between the control group (group 1) and each of the 
research groups (ie, group 1 vs group 2 and group 1 vs 
group 3). Each comparison was analysed using a 
two-sided 97·5% CI, to take the multiple comparisons 
into account. To calculate sample size, we estimated that 
70% of patients would enter the trial following the IPS 
pathway with an estimated median progression-free 
survival of 18 months, and 30% of patients would follow 
the DPS pathway with an estimated median progression-
free survival of 12 months, resulting in an overall median 
progression-free survival of 16·2 months. Assuming 
exponential survival and comparing the treatment 
groups using an unadjusted log-rank test, 602 events 
were required for each comparison to achieve 90% power, 
resulting in a total sample size of 1485 patients.
The unadjusted log-rank test was used as the primary 
test to determine if there was a difference between the 
Kaplan-Meier survival curves. A Cox proportional 
hazards model was to be used as the primary estimation 
of treatment effect if the proportional hazards 
assumption was satisfied. However, if evidence of non-
proportional hazards was found, the restricted mean 
survival time was to be used as the primary measure 
of the estimation of the size of treatment effect. 
Safety was analysed as the worst grade reported for 
each event in the intention-to-treat population.
An exploratory analysis with limited power comparing 
groups 2 and 3 was preplanned, in the event that both 
research groups were found to significantly improve 
progression-free survival compared with the control group.
Figure 1: Trial profile
522 assigned to group 1 (3-weekly 
carboplatin plus 3-weekly paclitaxel)
3 did not start treatment because of 
rapid clinical deterioration
1 did not start treatment because of 
rapid clinical deterioration
1 did not start treatment because of 
rapid clinical deterioration
4 lost to follow-up or withdrawn 12 lost to follow-up or withdrawn 5 lost to follow-up or withdrawn
523 assigned to group 2 (3-weekly 
carboplatin plus weekly paclitaxel)
1566 patients were recruited and randomly 
assigned to treatment
521 assigned to group 3 (weekly carboplatin 
plus weekly paclitaxel)
519 received treatment
365 completed six cycles 
protocol-defined chemotherapy
454 completed six cycles 
platinum-based chemotherapy
13 had incomplete treatment data
522 received treatment
305 completed six cycles 
protocol-defined chemotherapy
454 completed six cycles 
platinum-based chemotherapy
11 had incomplete treatment data
520 received treatment
322 completed six cycles 
protocol-defined chemotherapy
437 completed six cycles platinum-based 
chemotherapy
7 had incomplete treatment data 
522 assessed at database lock
337 reported progression or death
181 alive (no progression)
523 assessed at database lock
338 reported progression or death
173 alive (no progression)
521 assessed at database lock
343 reported progression or death
173 alive (no progression)
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The independent data monitoring committee met 
annually and had overall oversight of all emerging data 
within the study. All analyses were done using Stata 
version 15. The trial is registered on ClinicalTrials.gov 
(number NCT01654146) and ISRCTN Registry (number 
ISRCTN10356387).
Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, or in the writing of the 
report. ECJ, ARC, ADC, and RK had full access to all 
the data in the study, and the Trial Management Group 
had final responsibility for the decision to submit for 
publication.
Results
Between June 6, 2011, and Nov 28, 2014, 1566 patients 
were recruited into ICON8 (522 were included in group 1, 
523 in group 2, and 521 in group 3). Baseline charac-
teristics were well balanced across groups (table 1). The 
median age was 62 years (IQR 54–68) and 1444 (93%) par-
ticipants were ECOG performance status 0–1, 1073 (69%) 
had high grade serous carcinoma, and 1119 (72%) had 
disease stage IIIC or higher. 746 (48%) of patients 
underwent IPS followed by chemotherapy, whereas 
779 (50%) patients entered the study with a plan to 
undergo DPS; these proportions are different to the 
70:30 ratio expected at trial conception. 41 (3%) patients 
for whom surgical intervention was not deemed to be 
appropriate joined the trial (table 1).
Five patients did not commence protocol treatment 
because of rapid clinical deterioration (figure 1; appendix 
p 1). Of the 1561 women who started chemotherapy, 
complete treatment information is available for 1530. In 
group 1, 365 (72%) of 506 patients completed six cycles 
of per-protocol therapy. This proportion was higher than 
Figure 2: Progression-free survival
(A) Overall. (B) Split by immediate and delayed surgery. IPS=primary cytoreductive surgery. DPS=delayed primary cytoreductive surgery.
Number at risk
(number censored)
Standard
Weekly paclitaxel
Weekly carboplatin–paclitaxel
0
522 (10)
523 (6)
521 (3)
6
471 (3)
489 (1)
468 (3)
12
354 (1)
384 (4)
385 (2)
18
251 (7)
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that in groups 2 (305 [60%] of 511) and 3 (322 [63%] of 
513). However, more than 85% of all women received 
six cycles of platinum-based chemo therapy (454 [90%] in 
group 1; 454 [89%] in group 2; and 437 [85%] in 
group 3; appendix p 1). The incidence of both dose delays 
and omissions was higher in groups 2 and 3, although 
the proportion of patients requiring a dose reduction 
was similar in all three groups (appendix p 1). To evaluate 
the effect of weekly dose-dense paclitaxel on treatment 
delivery, total administered dose and relative dose 
intensity was calculated for all patients. Of note, 
although median total carboplatin dose was similar in all 
groups (AUC30 [IQR 29–35] in group 1 vs AUC30 [29–34] 
in group 2 vs AUC33 [30–35] in group 3), the median 
total paclitaxel dose administered was higher in the 
two weekly dose-dense arms (1010 mg/m² [840–1050] vs 
1233 mg/m² [1020–1357] vs 1274 mg/m² [1042–1368]; 
appendix p 1), indicating that, although more treatment 
alterations occurred in groups 2 and 3, the paclitaxel 
dose was intensified with weekly dosing.
Information on surgery was available for 708 (91%) of 
779 patients who entered the trial with planned DPS. 
602 (77%) underwent interval cytoreductive surgery 
and complete cytoreduction was achieved in 331 (56%) 
patients of this cohort (appendix p 2). Neither the 
proportion of patients who proceeded to DPS nor sur-
gical outcome, as measured by cytoreductive status 
and incidence of perioperative complications, differed 
between the three groups.
On Feb 20, 2017, after a median follow-up of 
36·8 months, 1018 patients had disease progression or 
had died (337 in group 1, 338 in group 2, and 343 in 
group 3; figure 1). Evidence of non-proportional hazards 
was observed (group 1 vs group 2 p=0·011; group 1 vs 
group 2 p=0·051; figure 2), which, therefore, means that 
hazard ratios are not robust over time, and so the 
restricted mean survival time (RMST) is the most 
appropriate primary estimate of treatment effect. RMST 
for progression was 24·5 months (97·5% CI 23·0–26·0) 
in group 1, 24·9 months (24·0–25·9) in group 2, and 
25·4 months in group 3 (23·9–26·9). There was no 
statistically significant difference for progression-
free survival for either group (group 1 vs group 2 
log-rank p=0·35; group 1 vs group 3 log-rank p=0·51; 
figure 2). Median progression-free-survival was 
17·7 months (IQR 10·6–not reached) for group 1, 
20·8 months (11·9–59·0) for group 2, and 21·0 months 
(12·0–54·0) for group 3. 
A preplanned subgroup analysis was done to evaluate 
the effect of weekly chemotherapy on progression-
free survival in patients who had undergone IPS 
and those with a plan for DPS separately (figure 2B). 
In the IPS cohort, RMST for progression-free survival 
was 32·6 months (97·5% CI 30·7–34·5) in group 1, 
33·0 months (31·5–34·5) in group 2, and 33·3 months 
(31·5–35·1) in group 3, whereas in those patients 
planned for DPS, RMST was 18·6 (17·0–20·2), 19·1 
(18·0–20·3), and 19·6 months (18·0–21·2). Therefore, 
no interaction between surgical approach and weekly 
dose-dense treatment was detected. The superior 
progression-free survival observed for patients who 
underwent IPS reflects the different FIGO stage profile 
in this group compared with patients who entered with a 
plan for DPS (appendix p 3). Further exploratory analyses 
did not detect any heterogeneity of treatment effect in 
subgroups based on disease stage, ECOG performance 
status, or histological subtype (figure 3).
At the time of the primary progression-free survival 
analysis, 539 deaths had been reported (190 in group 1, 
178 in group 2, and 171 in group 3; 61% and 60% of total 
events required for the final overall survival analysis of 
each comparison in group 1 vs group 2 and group 1 vs 
group 3, respectively). Estimated 2-year survival was 80% 
Figure 3: Subgroup analysis of progression-free survival. 
(A) Group 1 versus group 2. (B) Group 1 versus group 3. ECOG=Eastern Cooperative Oncology Group.  
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(95% CI 76–83) in group 1, 82% (78–85) in group 2, and 
78% (74–81) in group 3 (appendix p 5). A further six deaths 
have since been identified as occurring before Feb 20, 2017, 
but these events are not included in the analysis because 
they were not reported before the database lock.
The toxic effects experienced by patients during trial 
chemotherapy are given in detail in table 2 and appendix 
(p 4). Grade 3 or 4 toxic effects were reported in 213 (42%) 
patients in group 1, 320 (62%) patients in group 2, 
and 269 (53%) patients in group 3. The major contributor 
to the higher incidence of grade 3 or higher events 
in both weekly treatment groups was uncomplicated 
neutropenia, which occurred in 76 (15%) of 508 patients 
in group 1, 181 (35%) of 513 patients in group 2, and 
152 (30%) of 510 patients in group 3. This increase might 
partly be explained by the requirement for weekly full 
blood count evaluations in groups 2 and 3 compared 
with every 3 weeks evaluations in group 1. The incidence 
of febrile neutropenia was low across all three groups 
with 21 (4%) in group 1, 31 (6%) in group 2, and 16 (3%) in 
group 3, with no significant difference between groups 2 
or 3 and group 1 (group 1 vs group 2 difference 2% 
[95% CI –0·7 to 4·7], p=0·14; group 1 vs group 3 difference 
–1% [–3·3 to 1·3], p=0·39). However, the incidence of 
grade 3 or higher anaemia was significantly higher in 
patients assigned to group 2 compared with those 
receiving standard 3-weekly chemotherapy (25 [5%] in 
group 1 vs 65 [13%]in group 2, difference 8% [4·5–11·5]; 
p<0·0001]) but not in patients assigned to group 3 
(24 [5%], difference 0% [–2·7 to 2·7]; p=1·00).
194 (12%) trial participants experienced a chemothe-
rapy-related hypersensitivity reaction during treatment 
(appendix p 4). Although the incidence of reactions to 
paclitaxel was not affected by weekly scheduling (patients 
experiencing at least one hyper sensitivity reaction 
57 [11%] in group 1 vs 36 [7%] in group 2 vs 47 [9%] in 
group 3), the incidence of carboplatin hypersensitivity 
reactions was significantly higher in group 3 (3 [1%] vs 
4 [1%] vs 40 [8%]). Most carboplatin hypersensitivity 
reactions were mild (61 [92%] grade 1 or 2; 4 [6%] 
grade 3; 1 [2%] grade 4) and could be managed using 
increased hypersensitivity prophylaxis, slower chemo-
therapy infusion rates, or formal desensitisation 
protocols according to the ICON8 clinical guidance 
document. However, more patients in group 3 discon-
tinued carboplatin because of hypersensitivity than in 
groups 1 and 2.
The toxicity profiles were otherwise similar in all 
three groups. Of note, despite the higher dose of 
paclitaxel in groups 2 and 3, there were no significant 
differences in the incidence of grade 2 or higher sensory 
neuropathy between treatment groups (143 [27%] vs 
126 [24%] vs 117 [22%]).
The primary quality-of-life outcome endpoint was the 
global score, an overall measure of health and quality of 
life. Repeated measures longitudinal analysis of the period 
from randomisation to 9 months found significantly 
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improved quality of life with 3-weekly treatment (group 1 
vs group 2 p=0·043; group 1 vs group 3 p=0·0018). 
However, cross-sectional analysis 9 months after 
randomisation showed similar quality of life in all three 
groups at that time point (group 1 vs group 2 p=0·094; 
group 1 vs group 3 p=0·61). Detailed quality of life analysis 
will be reported separately.
Discussion
The results of the ICON8 trial show that it is feasible to 
deliver weekly dose-dense paclitaxel in combination with 
either 3-weekly or weekly carboplatin in the first-line 
treatment of high-risk ovarian cancer. However, neither 
of these regimens is associated with an improvement in 
survival outcomes compared with standard 3-weekly 
carboplatin–paclitaxel treatment in the predominantly 
European population treated on this trial.
ICON8 has many strengths. It was a large, international 
study that included both patients who received upfront 
primary surgery and neoadjuvant chemotherapy with 
delayed primary surgery, consistent with current 
standard practice. Chemotherapy completion was high, 
with over 85% of all patients receiving at least six cycles 
of platinum-based chemotherapy. Notably, although 
delivery of weekly dose-dense chemotherapy resulted in 
more dose delays and omissions compared with 3-weekly 
treatment, a significant increase in paclitaxel dose-
density was achieved in both weekly treatment groups 
without any negative effect on carboplatin dose. This 
result means that the key treatment goal of the trial was 
met, reinforcing the applicability of the trial results.
The recruitment of women with early stage high-risk 
ovarian cancer to the same trial as those with bulky 
inoperable stage III and stage IV disease could be 
considered a possible weakness of the design. However, 
subset analyses based on stage and surgical timing 
did not identify any heterogeneity in survival outcomes, 
supporting our eligibility criteria. It should also be noted 
that, although ICON8 had participation from five 
international trials groups, almost 90% of recruitment 
took place in the UK, meaning that it is not possible 
to explore any potential differences in the efficacy of 
dose-dense paclitaxel among different ethnic groups 
within this trial.
The ICON8 trial was conceived following the 
JGOG3016 trial,14,15 which found that in Japanese women 
with newly-diagnosed ovarian cancer, weekly dose-dense 
paclitaxel at a dose of 80 mg/m² administered with 
3-weekly carboplatin was more efficacious than con-
ventional 3-weekly carboplatin–paclitaxel chemo therapy 
with clinically significant improvements in both pro-
gression-free survival and overall survival albeit at the 
expense of greater treatment-related toxicity (table 3). 
Although we were unable to show a similar survival 
benefit from weekly dose-dense paclitaxel in combination 
with either 3-weekly or weekly carboplatin in ICON8, 
both dose-dense regimens were better tolerated in our 
predominantly European population with 85% of 
patients in all our study groups receiving six cycles of 
platinum-based chemotherapy compared with only 62% 
of those allocated to weekly chemotherapy in JGOG3016. 
Notably, the reported incidence of key grade 3 or higher 
chemotherapy-related toxic effects was lower in both the 
3-weekly and weekly dose-dense treatment groups in 
ICON8. The incidence of febrile neutropenia in group 2 
(3-weekly carboplatin and weekly paclitaxel) of ICON8 
was 6% compared with 9% in the identical treatment 
group in JGOG3016. Similar trends were observed 
for grade 3 or higher peripheral sensory neuropathy 
(4% vs 7%) and grade 3 or higher anaemia (13% vs 69%) 
indicating tolerability of carboplatin–paclitaxel is differ-
ent between the two study populations.
Two further large phase 3 randomised studies, done 
during the lifetime of the ICON8 study, have also 
investigated weekly chemotherapy administration in first-
line ovarian cancer treatment and are summarised in 
table 3. The European MITO-7 trial24 evaluated the 
concept of weekly chemotherapy scheduling without 
dose intensification. It recruited 822 women with FIGO 
stage IC–IV epithelial ovarian cancer who received 
conventional 3-weekly carboplatin–paclitaxel or weekly 
scheduling of both carboplatin (AUC2) and paclitaxel 
(60 mg/m²) for 18 weeks. No difference in efficacy was 
observed between the two treatment groups, although 
patients allocated to weekly treatment experienced less 
toxicity and had superior quality of life during treatment. 
In particular, incidence of febrile neutropenia (0·5% vs 3%) 
and grade 2 or higher sensory neuropathy (6% vs 17%) 
Number of patients HR (95% CI) Number of patients HR (95% CI)
3-weekly carboplatin 
and paclitaxel
3-weekly carboplatin 
and weekly paclitaxel
3-weekly carboplatin 
and paclitaxel
Weekly carboplatin 
and paclitaxel
ICON8* 522 523 0·9 (0·77–1·05) 522 521 0·93 (0·78–1·08)
JGOG 3016 319 312 0·65 (0·53–0·80) ·· ·· ··
GOG-0262† 57 55 0·62 (0·4–0·95) ·· ·· ··
MITO-7 ·· ·· ·· 404 406 0·96 (0·8–1·16)
HR=hazard ratio. *For the purposes of comparison, 95% CIs are used in this table; however, 97·5% CIs were used for the main analysis because of multiple testing. †Patients 
were given the option to receive bevacizumab in addition to randomised treatments; only patients who did not receive bevacizumab are included in this table.
Table 3: Summary of progression-free survival outcomes in phase 3 trials evaluating weekly first-line chemotherapy in epithelial ovarian cancer
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were significantly lower in patients receiving weekly 
chemo therapy. Notably, quality of life, measured weekly 
using the Functional Assessment of Cancer Therapy-
Ovarian Trial Outcome Index, deteriorated transiently 
1 week after each treatment cycle, during standard 
3-weekly chemo therapy. This pattern was not observed 
during weekly scheduling and the treatment-by-time 
interaction favoured weekly chemotherapy in all quality-
of-life analyses indicating that weekly carboplatin (AUC2) 
and paclitaxel (60 mg/m²) might be an attractive 
alternative to 3-weekly scheduling for selected patients. 
In parallel, the Gynecologic Oncology Group 262 trial 
enrolled 692 women with stage II–IV epithelial ovarian 
cancer who were randomly assigned to 3-weekly 
carboplatin–paclitaxel or 3-weekly carboplatin and weekly 
intensified paclitaxel (80 mg/m²).25 Concurrent and 
maintenance bevacizumab was permitted in both groups 
at patient or investigator choice and was administered to 
84% of trial participants. Intention-to-treat analysis did 
not show any improvement in efficacy with weekly 
paclitaxel chemotherapy nor indicate any significant 
reduction in treatment tolerability or increased toxicity. In 
contrast to MITO-7, a small statistically significant 
detriment in quality of life was observed in patients 
receiving weekly intensified paclitaxel, albeit at a level 
considered unlikely to have clear clinical relevance. 
However, in the subgroup of patients who did not receive 
bevacizumab (n=112), weekly paclitaxel administration 
was associated with a 4-month median progression-free 
survival improvement (HR 0·62 [95% CI 0·40–0·95]; 
p=0·03). Although it is possible that this improvement 
was a true treatment effect of weekly dose-dense paclitaxel 
that is masked in the whole trial population by the effect 
of maintenance bevacizumab, the small size of the no 
bevacizumab subgroup means that this result must be 
interpreted with caution. Caution is particularly relevant 
given the lack of benefit observed with weekly dose-dense 
paclitaxel in over 1000 women in the ICON8 trial.
It is possible that ethnic pharmacogenomic differences 
underlie the discordant outcomes between ICON8 
and JGOG3016, and that weekly dose-dense paclitaxel 
treatment could still be considered as a first-line treatment 
option for Japanese women with epithelial ovarian cancer. 
An analysis of parallel US and Japanese phase 3 trials 
evaluating 3-weekly carboplatin–paclitaxel in advanced 
lung cancer showed superior survival outcomes and 
higher proportions of haematological toxicity in Japanese 
patients with paclitaxel-based chemotherapy that on 
exploratory analysis were associated with ethnically 
distributed single nucleotide polymorphisms (SNPs) 
CYP3A4*1B and ERCC2K751Q.26 SNPs near AIPL1 
and BCR have also been associated with paclitaxel-
induced cytotoxicity in an Asian population.27 Of note, 
the longer survival and reduced tolerability of both 
3-weekly chemotherapy and weekly dose-dense paclitaxel 
in the JGOG3016 patient group compared with that 
observed in ICON8 support the potential for relevant 
pharmacogenomic differences that might affect treatment 
outcomes in patients with epithelial ovarian cancer and 
identifies an area for further research.
In conclusion, the results of the ICON8 trial provide 
evidence that weekly dose-dense paclitaxel should not be 
incorporated as a standard-of-care component of first-
line multimodality treatment of epithelial ovarian cancer 
for women who are not of Japanese ethnic origin.
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